


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 02307K-141581US
UCLA Reference No.: 97-575-B



On May 5, 2006
TOWNSEND and TOWNSEND and CREW LLP

By Karen Karlin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert E. Reiter et al.

Application No.: 09/854,811

Filed: May 14, 2001

For: METHODS FOR INDUCING AN
IMMUNE RESPONSE TO CANCERS
EXPRESSING PSCA

Customer No.: 20350

Confirmation No.: 9472

Examiner: Larry Ronald Helms

Art Unit: 1642

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A&B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

05/09/2006 SDENBOB1 00000036 201430 09854811

01 FC:1806 180.00 DA

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


This IDS is being filed on or before payment of the issue fee.

CERTIFICATION


I hereby certify that no item of information contained in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
ASP:kk



Substitute for form 1449A&B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 09/854,811 |
| Filing Date | May 14, 2001 |
| First Named Inventor | Reiter, Robert E. |
| Art Unit | 1642 |
| Examiner Name | Larry Ronald Helms |
| Attorney Docket Number | 02307K-141581US |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| | A | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|--|---|--------------------------|
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | | | | | | | <input type="checkbox"/> |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|--------------------------|
| | AA | JENS DANNULL ET AL., <i>Prostate Stem Cell Antigen Is a Promising Candidate for Immunotherapy of Advanced Prostate Cancer</i> , Cancer Research, October 1, 2000, pp. 5522-5528, Volume 60. | <input type="checkbox"/> |
| | AB | SATOKO MATSUEDA ET AL., <i>A Prostate Stem Cell Antigen-Derived Peptide Immunogenic in HLA-A24 Prostate Cancer Patients</i> , The Prostate, 2004, pp. 205-213, Vol. 60, Wiley-Liss, Inc. | <input type="checkbox"/> |
| | AC | ANDREA KIESSLING ET AL., <i>Prostate Stem Cell Antigen: Identification of Immunogenic Peptides and Assessment of Reactive CD8+ T Cells in Prostate Cancer Patients</i> , Int. J. Cancer, 2002, pp. 390-397, Vol. 102, Wiley-Liss, Inc. | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.